Advantageous salts of mu-opiate receptor peptides

Abstract

The subject invention provides advantageous new salts of mu-opiate receptor peptides. These salts have been found to have excellent properties in terms of their crystal structure, stability, solubility, lack of impurities and/or the ability to be produced, with these advantageous properties, in amounts sufficient for the production of therapeutic compositions.

What is claimed: 
     
         1 . A peptide salt wherein the peptide has a sequence selected from SEQ ID NOs: 1-26 and the salt is selected from the group consisting of maleate, hydrochloride, and lactate. 
     
     
         2 . The peptide salt, according to  claim 1 , wherein the peptide is SEQ ID NO:13. 
     
     
         3 . The peptide salt, according to  claim 2 , wherein the salt is the hydrochloride salt. 
     
     
         4 . A pharmaceutical composition comprising a peptide salt wherein the peptide has a sequence selected from SEQ ID NOs: 1-16 and the salt is selected from the group consisting of maleate, hydrochloride, and lactate. 
     
     
         5 . The pharmaceutical composition, according to  claim 4 , wherein the peptide is SEQ ID NO:13. 
     
     
         6 . The pharmaceutical composition, according to  claim 5 , wherein the salt is the hydrochloride salt. 
     
     
         7 . The pharmaceutical composition, according to  claim 4 , further comprising 2-Hydroxypropyl-β-cyclodextrin. 
     
     
         8 . A method for treating a condition that is modulated by μ-opiate receptor activity, wherein said method comprises administering, to a patient in need of such treatment a peptide salt wherein the peptide has a sequence selected from SEQ ID NOs: 1-26 and the salt is selected from the group consisting of maleate, hydrochloride, and lactate. 
     
     
         9 . The method, according to  claim 8 , wherein the peptide is SEQ ID NO:13. 
     
     
         10 . The method, according to  claim 9 , wherein the salt is the hydrochloride salt. 
     
     
         11 . The method, according to  claim 8 , which is used to provide analgesia or to treat a condition selected from the group consisting of gastrointestinal disorders, inflammation, and drug dependence. 
     
     
         12 . The method, according to  claim 8 , wherein the composition further comprise 2-Hydroxypropyl-β-cyclodextrin.